| Autor: |
Libardi Lira Machado, Ketty Lysie, da Costa-Rocha, Ismael Artur, Gonçalves Rodrigues Aguiar, Laura, Ribeiro Moulaz, Isac, Tatiyama Miyamoto, Samira, Costa Martins, Priscila, Vieira Serrano, Erica, Espíndula Gianordoli, Ana Paula, da Penha Gomes Gouvea, Maria, de Fatima Bissoli, Maria, Maria Barbosa de Lima, Sheila, Dias Schwarcz, Waleska, de Souza Azevedo, Adriana, Fernandes Amorim da Silva, Juliana, Tourinho Santos, Renata, Pedro Brito-de-Sousa, Joaquim, Coelho-dos-Reis, Jordana Grazziela, Campi-Azevedo, Ana Carolina, Teixeira-Carvalho, Andréa, Peruhype-Magalhães, Vanessa, Fontana Sutile Tardetti Fantinato, Francieli, Maria Henrique da Mota, Licia, Assis Martins-Filho, Olindo, Valim, Valéria |
| Zdroj: |
Human Vaccines & Immunotherapeutics; December 2024, Vol. 20 Issue: 1 |
| Abstrakt: |
ABSTRACTThe present study aimed at investigating whether the hydroxychloroquine (HCQ) treatment would impact the neutralizing antibody production, viremia levels and the kinetics of serum soluble mediators upon planned 17DD-Yellow Fever (YF) primovaccination (Bio-Manguinhos-FIOCRUZ) of primary Sjögren’s syndrome (pSS). A total of 34 pSS patients and 23 healthy controls (HC) were enrolled. The pSS group was further categorized according to the use of HCQ (HCQ and Non-HCQ). The YF-plaque reduction neutralization test (PRNT ≥1:50), YF viremia (RNAnemia) and serum biomarkers analyses were performed at baseline and subsequent time-points (Day0/Day3–4/Day5–6/Day7/Day14-D28). The pSS group showed PRNT titers and seropositivity rates similar to those observed for HC (GeoMean = 238 vs440, p = .11; 82% vs96%, p = .13). However, the HCQ subgroup exhibited lower seroconversion rates as compared to HC (GeoMean = 161 vs440, p = .04; 69% vs96%, p = .02) and Non-HQC (GeoMean = 161 vs337, p = .582; 69% vs94%, p = .049). No differences in YF viremia were observed amongst subgroups. Serum biomarkers analyses demonstrated that HCQ subgroup exhibited increased levels of CCL2, CXL10, IL-6, IFN-γ, IL1-Ra, IL-9, IL-10, and IL-2 at baseline and displayed a consistent increase of several biomarkers along the kinetics timeline up to D14–28. These results indicated that HCQ subgroup exhibited a deficiency in assembling YF-specific immune response elicited by 17DD-YF primovaccination as compared to Non-HCQ subgroup. Our findings suggested that hydroxychloroquine is associated with a decrease in the humoral immune response after 17DD-YF primovaccination. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
